Yale and NFCR launch Research Center for Cancer Drug Design and Discovery

October 13, 2006

New Haven, Conn. -- Yale University and the National Foundation for Cancer Research (NFCR) announced the establishment of an NFCR Center for Anti-Cancer Drug Design and Discovery to develop new beta-peptide inhibitors that will play critical roles in the fight against many types of cancer.

Funded by a five-year, $750,000 grant from the NFCR, the center will be led jointly by Alanna Schepartz, the Milton Harris, '29 Ph.D. Professor of Chemistry, and William Jorgensen, the Whitehead Professor of Chemistry at Yale.

"We are delighted that the NFCR has chosen to support Yale as a place where cutting-edge drug discovery research in chemistry is making, and will continue to make, an impact in the fight against cancer," said Yale Provost Andrew Hamilton.

The new NFCR Center will work to develop a better understanding of how ß-peptides can be designed to disrupt protein-protein interactions that transmit cell signals. When proteins behave abnormally, they often send incorrect signals that result in uncontrolled cell growth and division, and cancer. In their research, Schepartz and Jogensen will focus on developing new, more effective approaches to inhibit these abnormal protein-protein interactions and thereby block transmissison of cellular signals that lead to cancer growth.

Unlike the most commonly used small molecule inhibitors, ß-peptides have a chemical structure very similar to that of their target proteins, allowing the drug to bind the target proteins more specifically and inhibit them more effectively. The Schepartz/Jorgensen team will use both cutting-edge experimental chemistry and elegant computer modeling to design and optimize ß-peptide inhibitors of a wide range of targets. Since ß-peptides are stable within the human body, their research has the potential to create a completely new technology platform for more effective and long-lasting anticancer drugs.

"This new center provides a vital link among the worldwide network of NFCR sponsored scientists that will significantly move our protein research to the forefront of cancer research," Schepartz said. "At Yale, we believe in the value of exploring every avenue in our quest to cure cancer, and with this partnership between NFCR and the university, we move one step closer to that goal."

The NFCR Center at Yale will collaborate with over 40 additional cancer researchers at universities and hospitals worldwide, and become a part of one of the largest cancer research networks in the world. Other NFCR Centers are at Oxford, Case Western Reserve, University of Alabama-Birmingham, University of California-Berkeley, Dana Farber Cancer Center, University of Arizona, Freie Universität Berlin, and the Institute of Medicinal Biotechnology in Beijing to form a broader international collaborative network of top researchers.

"The NFCR Center for Anti-Cancer Drug Design and Discovery at Yale University, will provide a new and vital link to the development of drug design that will undoubtedly lead to new, novel anticancer drugs that will help save lives," said Franklin Salisbury, Jr., President of the National Foundation for Cancer Research.

The Center was launched today at a mini-symposium in the new Class of '54 Chemical Research Building on Science Hill. In addition to Directors Schepartz and Jorgensen, speakers included NFCR President Franklin Salisbuty, Jr., and Yale Provost Andrew Hamilton.
-end-
Since it's founding in 1973, NFCR has spent more than $230 million funding basic science cancer research and cancer prevention education focused on understanding how and why cells become cancerous. NFCR is dedicated to funding scientists who are discovering cancer's molecular mysteries and translating these discoveries into therapies that hold the hope for curing cancer. For more information, visit www.NFCR.org or call 1-800-321-CURE (2873).

National Foundation for Cancer Research http://www.NFCR.org
Alanna Schepartz http://www.chem.yale.edu/faculty/schepartz.html
William Jorgenses http://www.chem.yale.edu/faculty/jorgensen.html
Andrew Hamilton http://www.yale.edu/provost/html/office.html

Yale University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.